H. McElwaine-Johnn, G. Golor, R. Handy
2013
Citations
0
Influential Citations
1
Citations
Quality indicators
Journal
Neurourology and Urodynamics
Abstract
Hypothesis / aims of study Fedovapagon (VA106483), a novel non-peptide drug, is a selective vasopressin V2-receptor agonist in development for the treatment of nocturia. The purpose of this study was to establish the dose response relationship of fedovapagon and nocturnal urine volumes (NUV), nocturnal void frequency and time to first void in a population of males aged 65 years and over with benign prostatic hyperplasia (BPH) and nocturia.